Arcellx Inc (ACLX)

Currency in USD
70.67
-1.37(-1.90%)
Closed·
After Hours
70.670.00(0.00%)
·
ACLX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 11 days
ACLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
69.4772.06
52 wk Range
47.86107.37
Key Statistics
Prev. Close
72.04
Open
72.06
Day's Range
69.47-72.06
52 wk Range
47.86-107.37
Volume
491.58K
Average Volume (3m)
645.35K
1-Year Change
36.83%
Book Value / Share
7.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACLX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
113.80
Upside
+61.03%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Arcellx Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Arcellx Inc Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Arcellx Inc SWOT Analysis


Promising Myeloma Therapy
Arcellx's anito-cel shows potential best-in-class efficacy and safety in multiple myeloma treatment, with 97% overall response rate in clinical trials
Market Disruption Ahead
Analysts project CAR-T therapies could capture 30% of multiple myeloma market, positioning Arcellx for significant growth in a competitive landscape
Financial Horizon
Despite current losses, Arcellx maintains strong liquidity. Analysts forecast EPS of -$1.47 for FY 2023, -$1.53 for FY 2024, and -$4.27 for FY 2025
Bullish Outlook
Analysts maintain strong buy consensus with high target of $134. Barclays and Canaccord set price targets at $115 and $121, respectively
Read full SWOT analysis

Compare ACLX to Peers and Sector

Metrics to compare
ACLX
Peers
Sector
Relationship
P/E Ratio
−24.0x−1.8x−0.5x
PEG Ratio
0.13−0.070.00
Price/Book
9.3x2.9x2.6x
Price / LTM Sales
50.7x66.2x3.3x
Upside (Analyst Target)
55.5%181.9%43.5%
Fair Value Upside
Unlock10.6%6.9%Unlock

Analyst Ratings

18 Buy
0 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 113.80
(+61.03% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-1.13 / -0.76
Revenue / Forecast
8.13M / 19.36M
EPS Revisions
Last 90 days

ACLX Income Statement

People Also Watch

263.10
AVAV
-0.62%
111.26
INSM
-0.31%
92.98
MMYT
+0.26%
746.37
LLY
-2.56%

FAQ

What Stock Exchange Does Arcellx Trade On?

Arcellx is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Arcellx?

The stock symbol for Arcellx is "ACLX."

What Is the Arcellx Market Cap?

As of today, Arcellx market cap is 3.97B.

What Is Arcellx's Earnings Per Share (TTM)?

The Arcellx EPS (TTM) is -3.00.

When Is the Next Arcellx Earnings Date?

Arcellx will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is ACLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Arcellx Stock Split?

Arcellx has split 0 times.

How Many Employees Does Arcellx Have?

Arcellx has 163 employees.

What is the current trading status of Arcellx (ACLX)?

As of 07 Aug 2025, Arcellx (ACLX) is trading at a price of 70.67, with a previous close of 72.04. The stock has fluctuated within a day range of 69.47 to 72.06, while its 52-week range spans from 47.86 to 107.37.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.